BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06220604 (icotrokinra in Moderate to Severe Plaque Psoriasis): BVCT ex-ante prediction vs. reported outcome

On 14 Jan 2025, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 17 Sep 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (oral).

Clinical Trial

NCTID
NCT06220604
Acronym
ICONIC-ADVANCE 2
Drug Name
icotrokinra (JNJ-2113)
Drug MoA
oral anti-IL23R antagonist
Drug Modality
peptide
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
Moderate to Severe Plaque Psoriasis
Human Patients
731
Sponsor
Johnson & Johnson / Protagonist Therapeutics
Phase
Phase 3

Prediction of , index 1871

Prospective Prediction
Prediction Index
1871
Prediction Date
Commercial Prediction
partial SUCCESS (commercially sufficient yet moderate clinical benefit in IGA0/PASI90 non-superior to bimekizumab)
Technical Prediction
SUCCESS (statistically significant clinical benefit in IGA0/PASI90 superior to deucravacitinib)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
246 days in advance
Readout Data Interpretation
icotrokinra achieved 56% placebo-adjusted PASI90 at week 16 (p<0.0001); superior to deucravacitinib in the same trial; yet inferior to bimekizumab’s 90% placebo-adjusted PASI90 at week 16 (see add'l link below)
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (oral)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Phase
Phase 3
Status
Active not recruiting
Enrollment
731
Lead sponsor
Janssen Research & Development, LLC
Conditions
Plaque Psoriasis
Interventions
DRUG: JNJ-77242113; DRUG: JNJ-77242113 Matching Placebo; DRUG: Deucravacitinib; DRUG: Deucravacitinib Matching Placebo
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2024-03-09
Primary completion
2024-11-15
Completion
2027-09-20
Results first posted
2026-06-25
Primary outcomes
  • Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16)
  • Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16 (Week 16)

NCT06220604 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials